Prostate Cancer

Aspirin has a more developed evidence base in prostate cancer than many readers realise.

This is not just a prevention story. The literature also includes post-diagnosis survival data, a 2025 post-surgical recurrence study, and two biomarker-defined subgroups that may help explain why some studies look clearly supportive while others look neutral. Read the summary

That makes prostate cancer one of the more important aspirin pages outside colorectal cancer.

Overview

Prostate cancer is common, but not biologically uniform.

Many cases are slow-growing. High-grade and metastatic disease is much more dangerous. Aspirin appears to matter most at the more aggressive end of the spectrum, where inflammation, COX-2, TXA2, androgen-signalling crosstalk, and metastatic biology become more relevant. Read the 2025 paper

This page matters because the signal is not only epidemiological. It also includes:

• post-diagnosis mortality data

• biochemical-recurrence data after surgery

• subtype-specific molecular signals

• direct tumour-tissue gene-expression findings in aspirin users

Key human data

Prevention

Several prostate-cancer datasets support a preventive signal, especially for more aggressive disease.

• Physicians' Health Study: In 22,071 men followed for 27 years, regular aspirin use at three or more tablets per week was associated with about 24% lower risk of lethal prostate cancer. Read the summary

• Population cohort with inflammatory-genotype signal: Men using aspirin or ibuprofen at least twice per week for more than a month had about 33% lower prostate-cancer risk overall. In men carrying the LTA gene variant, the reduction reached 57%. Men without the variant did not show the same benefit. Read the report

• 2025 Danish low-dose aspirin cohort: Prostate cancer was among the tumour types showing lower risk with sustained long-term low-dose aspirin use. Read the cohort paper

• Meta-analyses: Most summaries place the reduction in overall incidence somewhere in the 10% to 33% range, with stronger protection often reported for more aggressive or lethal prostate cancer rather than indolent disease. Read the review

That pattern matters.

Aspirin may be less relevant to low-risk, slow-growing prostate cancer than to the inflammatory, high-grade, or metastatic end of the disease.

Post-diagnosis survival

This is where the literature becomes more interesting and more complicated.

• Physicians' Health Study, post-diagnosis analysis: Regular aspirin use after diagnosis was associated with about 39% lower prostate-cancer-specific mortality. Read the summary

• Conflicting survivor cohort: Another study of prostate-cancer survivors found no significant association between post-diagnosis aspirin use and lethal disease after adjusting for Gleason score, stage, and treatment type. Read the paper

That conflict should not be hidden.

It is one of the clearest examples in this section of why unselected populations can blur a real subgroup effect.

Biochemical recurrence after radical prostatectomy

The 2025 Nature Scientific Reports paper is one of the most clinically useful prostate-cancer aspirin datasets.

It looked at men undergoing robot-assisted radical prostatectomy, or RARP, which is now a common surgical approach for localised disease. Aspirin users had better biochemical recurrence-free survival overall after surgery. Read the paper

The strongest signal was in high-risk disease.

Men with ISUP grade 4 or higher showed hazard ratios of about 0.44 to 0.45, which translates to roughly 55% to 56% lower risk of biochemical recurrence compared with non-users. Read the paper

That is a striking result because the men with the most aggressive tumours appeared to benefit the most.

Molecular biomarkers and subgroups

LTA gene variant

This is one of the more interesting biomarker stories in the aspirin literature.

The lymphotoxin-alpha, or LTA, gene variant appears to define an aspirin-sensitive inflammatory subtype. In the reported cohort, men with this variant had about 57% lower prostate-cancer risk with regular aspirin or ibuprofen use, while men without the variant did not show a significant benefit. Read the report

This is not yet a clinical standard biomarker.

But conceptually it is very important. It suggests prostate cancer may have an aspirin-sensitive molecular subgroup in the same way colorectal cancer has a PIK3CA-selected subgroup.

TMPRSS2:ERG fusion

The TMPRSS2:ERG gene fusion is present in about half of prostate cancers and is one of the most common molecular alterations in the disease.

Prospective cohort work has suggested that aspirin use is associated with lower risk of ERG-positive prostate cancer specifically. That implies aspirin may act differently across molecular subtypes rather than affecting prostate cancer as a single category. Read the paper

This is still observational.

But it is one of the strongest subtype-specific clues in prostate-cancer aspirin research.

High ISUP grade disease

The 2025 radical-prostatectomy study effectively adds another subgroup marker.

Men with ISUP grade 4 or higher showed the clearest recurrence benefit after surgery. That makes high-grade disease one of the most practical current subgroups for aspirin discussion. Read the paper

Mechanistic relevance

COX-2, PGE2, and androgen-receptor crosstalk

One of the more prostate-specific aspirin mechanisms is the overlap between prostaglandin signalling and the androgen receptor, or AR.

In prostate-cancer models, aspirin has been shown to increase EP3 receptor expression, which then helps suppress AR expression through NF-κB-related signalling changes. Lower AR signalling can reduce prostate-cancer-cell survival. Read the mechanistic paper

That gives aspirin a biologically distinctive place in prostate cancer.

It is not just an inflammation drug here. It also intersects with one of the main lineage-defining pathways of the tumour.

TXA2 and platelet biology

The thromboxane pathway is also highly relevant in prostate cancer.

TXA2 synthase and the thromboxane receptor, or TPr, are elevated in malignant prostate cells compared with non-cancerous prostate cells. Their expression also correlates with Gleason score and pathological stage. Read the paper

That matters because prostate cancer often spreads to lymph nodes and bone, where platelet-assisted metastatic survival may become important. The 2025 Nature work on the TXA2 → ARHGEF1 → CD8-positive T-cell suppression axis gives this pathway more systemic meaning. Read the Cambridge summary

For the broader mechanism, see Aspirin and Thromboxane A2 (TXA2).

Gene-expression changes in human tumour tissue

One of the most unusual prostate-cancer aspirin studies looked directly at gene expression in human prostate tumours from men who were regular aspirin users at diagnosis.

Aspirin exposure was associated with measurable ribosomal gene-expression changes in tumour tissue, and the derived expression signature was linked to prognosis. Read the paper

This matters because it goes beyond lab models.

It suggests aspirin can leave a measurable biological footprint inside actual human prostate tumours.

NF-κB suppression and castration resistance

NF-κB is constitutively active in castration-resistant prostate cancer, or CRPC, which is the more lethal and treatment-resistant state of the disease.

Aspirin's ability to suppress NF-κB therefore remains highly relevant in advanced prostate-cancer biology, even though there is still no dedicated CRPC aspirin trial. Read the mechanistic paper

Clinical positioning

Honest evidence assessment

The prostate-cancer aspirin story is supportive, but not simple.

The biggest tension is the survival literature. One major cohort suggests a real post-diagnosis mortality benefit. Another finds no clear effect after adjustment for grade, stage, and treatment.

The most plausible explanation is not that one study must be wrong.

The more plausible explanation is that aspirin benefit is subgroup-dependent and becomes diluted in unselected populations.

The strongest candidate subgroups right now are:

• men with high-grade disease

• men with the LTA inflammatory variant

• men with TMPRSS2:ERG-positive tumours

• possibly men in the post-prostatectomy recurrence-risk setting

That is what makes this page more advanced than it first appears.

Practical interpretation

For men with prostate cancer, the most useful questions are:

1. What was the tumour ISUP / Gleason grade, and was it grade 4 or higher?

2. Has the tumour been assessed for TMPRSS2:ERG fusion?

3. Is there access to LTA variant testing, or is that still research-only in this context?

4. Am I on androgen-deprivation therapy, and does aspirin's AR-related biology make the discussion more relevant?

5. Given cardiovascular benefit, GI risk, age, and bleeding risk, is low-dose aspirin a reasonable discussion with my treating team?

That is the most honest way to use the current evidence.

It is not a blanket prostate-cancer recommendation. It is a targeted, biology-aware discussion.

References

• Nature Scientific Reports 2025 — aspirin and biochemical recurrence-free survival after radical prostatectomy, strongest in ISUP grade 4 or higher disease. Read the paper

• Physicians' Health Study coverage — lower lethal prostate-cancer risk and lower post-diagnosis prostate-cancer mortality in regular aspirin users. Read the summary

• TMPRSS2:ERG subtype analysis — prospective cohort signal for lower risk of ERG-positive prostate cancer. Read the paper

• LTA-variant report — stronger risk reduction in the inflammatory-gene subgroup. Read the report

• Mechanistic prostate-cancer paper — aspirin, EP3, AR, and NF-κB crosstalk. Read the paper

• Human tumour-tissue gene-expression study — ribosomal expression changes linked to aspirin use. Read the paper

• Null survivor-cohort analysis — no clear post-diagnosis effect after adjustment. Read the paper

• Yang et al., Nature 2025 — platelet TXA2, immune escape, and metastatic spread. Read the Cambridge summary

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form